Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 15, 2023, serves as a current report for Bioaffinity Technologies, Inc., a Delaware corporation. The filing references the company's financial results for the three-month period ended March 31, 2023, which were detailed in a press release issued on the same date (attached as Exhibit 99.1).
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing acts as a notification of the results rather than a detailed financial statement. Investors must refer to the attached press release (Exhibit 99.1) for specific financial data.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It solely indicates that results for the quarter ended March 31, 2023, have been released.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, or specific risk factors. It includes a standard disclaimer stating that the information in this Form 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 15, 2023) for actual revenue, net income, and cash flow figures.
- Verify the company's status as an emerging growth company (indicated as yes in the filing).
- Check the Nasdaq Stock Market for trading activity of Common Stock (BIAF) and Tradeable Warrants (BIAFW).
- Confirm if the press release contains updated guidance or operational milestones not summarized in this 8-K.